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ABSTRACT

Heat Shock Protein 27 Inhibition of Apoptosis in Human Breast Cancer Cells
by
Sindhu Padmanabhan

Dr. Stephen W. Carper, Examining Committee Chair
Associate Professor o f Chemistry
University o f Nevada, Las Vegas.

Cancer occurs when normal cells fail to die in response to various cell
death signals. Normal eukaryotic cells exhibit two major forms o f cell death Necrosis and Apoptosis. Apoptosis can be triggered in cells by various agents.
Studies have shown that an elevated amount o f Hsp 27 protects cells from
apoptosis induced by Sodium Butyrate. In this study, we treated estrogen receptor
negative human breast cancer cells with apoptotic inducers such as Sodium
Butyrate, Staurosporine, Vitamin E Succinate and Cycloheximide. The cells that
constitutively expressed Hsp 27 had a higher growth in the presence o f
Cycloheximide and Vitamin E Succinate and also exhibited lesser apoptosis in the
presence o f Sodium Butyrate and Staurosporine. This study demonstrates that
Hsp 27 blocks cell death in breast cancer cells in the presence of certain cytotoxic
drugs and the presence o f this protein could serve as a marker for aggressive
tumors.
iii
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CHAPTER 1

INTRODUCTION

Cancer

Cancer is a cellular disease characterized by the uncontrolled proliferation
o f cells leading to a local growth or tumor. Tumors are a caricature o f the normal
processes o f tissue renewal; they arise when the normal processes o f growth and
differentiation go awry (1 ). In the normal cells that make up different parts o f our
body, each cell has a definite function and a predictable life cycle. The growth
and division o f normal cells is regulated by complex biochemical processes i.e.,
when a fully functional cell becomes senescent; it is shed and replaced by another
cell that takes it’s place. A cancerous growth results when the regulation o f the
cell cycle is upset and cells fail to respond to cell death signals.

A Faulty Regulation in Cancer Cells

Normal cells go through a specific number o f cell cycles after which they
die via a programmed cell death process known as apoptosis.

Apoptosis is

distinct mode o f cell death occurring during the normal processes o f growth and

1
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development (2). It is responsible for deletion o f cells in normal tissues and is
characterized by plasm a membrane blebbing, condensation of cytoplasm and
nucleus, and cellular fragmentation into membrane bound apoptotic bodies, which
are phagocytysed by neighboring cells (2-6)(Figure 1, page 3). Biochemically,
apoptosis is characterized by extensive endonucleolytic cleavage o f double
stranded DNA initially into large fragments o f 50-300 kilobases (6).

The

endonucleases then cleave the DNA at linker regions producing nucleosomes, 200
base pairs o f DNA wound around a histone octamer (Figure 2, page 4). Cells can
also die by necrosis, which involves swelling o f cytoplasm and organelles
followed by lysis o f plasma membrane and random DNA fragmentation (2). An
interesting feature o f apoptosis is that it can take place in isolated cells and unlike
necrosis does not generate an inflammatory response.

Apoptosis becomes

important in a pathological context too, its deregulation leading to disease
conditions such as cancer, neurodegeneration, ischemia, senescence and AIDS
(7). Since apoptosis can be induced in cells, knowledge o f its mechanism can be
a powerful tool in manipulating an apoptotic response in cancer and other
diseases.

Apoptosis as a Biochemical Process

Apoptosis can be induced in cells by a variety o f agents such as radiation
(ionizing and UV), chemotherapeutic drugs, heat, hypoxia, glucocorticoids
growth factor deprivation (2)(Figure 3, page 5). The exact mechanism(s)
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I
Figure 1

Î

Diagram illustrating the ultrastructural features o f apoptosis and
necrosis. (Adapted &om Kerr, et al., Cancer, 73:2014, 1994)
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by which these agents trigger apoptosis is not known but a family o f cysteine
proteases (related to the interleukin-ip-converting enzyme (ICE)) become
activated and execute apoptosis through specific cleavage o f substrates known as
death substrates (8,9). Cysteine proteases belong to the family o f enzymes that
degrade proteins.

These proteases have a reactive cysteine at its active site

(sulfhydryl site), which is responsible for catalyzing the cleavage o f peptide
bonds.
The cysteine proteases, the major effectors o f cell death, are present as
inactive precursor polypeptides that are activated during the death process by
cleavage at aspartic acid residues (9). These activated proteases cleave the death
substrates at specific aspartic acid residues too, and hence are known as cysteineaspases or Caspases (9,10,11).

Recent work has shown that there are eleven

mammalian caspases, which are divided into four classes on the basis o f their
molecular homology (9). The activated caspases go on to cleave (a) DNA repair
enzymes such as poly (ADP)-ribose polymerase and DNA dependent protein
kinase, DNA-PK, thereby abolishing the DNA repair ability in cells (b) Structural
proteins like lamin, leading to nuclear condensation, (c) Cytoskeletal proteins
including actin, Gas-2 and fodrin, inducing cell shrinkage and membrane
blebbing, (d) Small ribonucleoprotein U l-70kD a, and (e) cell cycle mediators
such as protein kinase C 8 and retinoblastoma protein Rb (11,12). Recently it has
been reported that caspases are also responsible for activating a calcium
dependent endonuclease, CAD, responsible for cleaving the DNA at the linker
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regions (Figure 2, page 4) between nucleosomes by specifically cleaving and
inactivating ICAD, the inhibitor o f CAD (13). Hence turning on caspases acts as
an irreversible signal for death by apoptosis.

Small Heat Shock Proteins and Apoptosis

Heat shock proteins (Hsp) are a unique family o f highly conserved
proteins produced by cells in response to environmental and pathophysiological
stresses (14,15,16). The heat shock family o f proteins is subdivided into four
major classes based on the molecular weight o f these proteins. They are Hsp 110,
Hsp 90, Hsp 70 and Small heat shock proteins (sHsp) which include Hsp 27.
Hsp’s are produced in response to environmental stresses such as heat shock, UV
radiation, heavy metals and oxidants, physiological stimulants such as hormones,
growth factors and cell cycle regulators, and pathophysiological conditions such
as infections and glucose starvation (16). The main function o f the Hsp 90 and
Hsp 70 class o f heat shock proteins is molecular chaperoning i.e., to preserve the
proteins within the stressed cell in a folded state so that they are not denatured
during the stress. In addition to the chaperoning function, these proteins are also
involved in signal transduction and thermotolerance. Small heat shock proteins
like Hsp 27 have been known to protect cells from oxidative stress, apoptosis and
chemotherapeutic drugs (4,5,17).
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Hsp 27 and Breast Cancer

In normal breast tissue, the expression o f Hsp 27 is very low whereas it is
present in very high amounts in human breast tumor cells (18). The presence o f
this protein is a prognostic marker for more aggressive tumors and indicates
shortened disease free survival and increased resistance to chemotherapeutic
drugs (19). Hsp 27 is an estrogen responsive protein. Mammary carcinoma cells
having receptors for estrogen (ER^) and also expressing Hsp 27 can be sensitized
to chemotherapeutic drugs by treating them with estrogen antagonists. Estrogen
antagonists are structurally similar to estrogen and bind to the estrogen receptor.
The antagonist binding inhibits estrogen from binding to its receptor, decreasing
the proliferative effects caused by the binding o f estrogen to its receptor. The
presence o f Hsp 27 in ER^ tumors is believed to increase the rate o f proliferation
o f these cancerous cells (20). However we have seen Hsp 27 protect estrogen
receptor negative (ER ) breast cancer cells from cytotoxic drugs and previous
work has shown that these ER cells can also be sensitized to doxorubicin, a
chemotherapeutic drug, by the estrogen antagonist toremifene (21). The exact
mechanism by which Hsp 27 confers protection to tumor cells against
chemotherapeutic drugs is still unclear.
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Significance o f the Study

The main goal o f this work is to understand the role o f Hsp 27 in ER'
breast cancer cells. The presence o f Hsp 27 in ER' breast cancer cells, as shown
by our study protects these cells from various cytotoxic drugs.

The exact

mechanism by which Hsp 27 confers protection is not known, but its ability to do
so at various points in the apoptotic pathway leads us to believe that it is acting
downstream to these inducers.
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CHAPTER 2

MATERIALS AND METHODS

Cell Lines

The cell lines used in this study are derived from the estrogen receptor
negative human breast cancer cells MBA-MD-231 by transfection with the
constitutive expression vector pP27 (DB 46 and DB 26) or the control vector
pHpApr-I-neo (DC 4 and DC 7) (21). Stable transfected cell lines were isolated
and grown in Minimal Essential Media (MEM) (Gibco BRL), supplemented with
10% fetal bovine serum, 25 mM HEPES buffer, 100 lU penicillin/ml, 1OOpg/ml
streptomycin, 2mM L-glutamine (Biowhittaker Inc.), and 600 pg/ml G418 sulfate
(Gibco BRL). All cultures were maintained at 37°C in humidified incubators with
5% CÜ 2 : 95% air. Twenty-four hours prior to an experiment, cells were washed
and resuspended in supplemented MEM, lacking G418.

Cytotoxic Drugs

Sodium Butyrate, Staurosporine, Vitamin E Succinate and Cycloheximide

10
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11
were used in this study because o f their reported capacity to act as apoptotic
inducers (25-37).

Growth inhibition and apoptosis induced by each drug was

studied using MTT assay and enzyme linked immuno absorbent assay (ELISA)
respectively (described in detail in separate sections). The drug treatment (i.e. the
incubation time with the drug) and concentration o f the drug varied with the drug
used.

Sodium Butyrate

Sodium Butyrate (Sigma Chemical Co.) was prepared in deionized water
(lOOmM).

Appropriate concentrations o f the drug was added to Hsp 27

expressing and control transfected cells, 24 hours after the cells were plated in a
96 well plate (this incubation is done to let the cells attach to the plate). Growth
inhibition was studied 24h and 48h after incubation with the drug. Apoptosis was
measured 24h after incubation with the drug.

Staurosporine

Staurosporine (Sigma Chemical Co.) was prepared in DMSO (100 pM).
Appropriate concentrations o f the drug was added to Hsp 27 expressing and
control transfected cells, 24 hours after the cells were plated in a 96 well plate.
Growth inhibition and apoptosis was studied 24h after incubation with the drug.
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Vitamin E Succinate

Vitamin E Succinate (Sigma Chemical Co.) was prepared in 100% ethanol
(5mM-15mM).

Succinic acid (Sigma Chemical Co.) prepared in ethanol

(1 mg/ml) was used as control. Appropriate concentrations o f the drug was added
to Hsp 27 expressing and control transfected cells, 24 hours after the cells were
plated in a 96 well plate. Growth inhibition was studied at 48h and 65h.

Cycloheximide

Cycloheximide (Sigma Chemical Co.) was prepared in 100% ethanol
(10mM-40mM). Appropriate concentrations o f the drug was added to Hsp 27
expressing and control transfected cells, 24 hours after the cells were plated in a
96 well plate. Various concentrations o f Cycloheximide was added at the end of
the incubation period and reincubated for 2h. At the end o f the incubation period
with the drug, 200pl media was removed and 200 pi o f fresh media was added to
wells and the plate was incubated at 37°C. Growth inhibition was measured 24h65h later.

Growth Assay

The growth o f the control transfected (DC 4 and DC 7) and Hsp27
expressing cell lines (DB46 and DB26) in the presence o f cytotoxic drugs was
measured using MTT (Sigma Chemical Co.) dye uptake procedure. The MTT
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assay is a quantitative colorimetric assay that is rapid and does not involve the use
o f any radioisotopes (22).

Br©

■CH3

■CH3

CH3

MTT

Figure 4

FORMAZAN

Reduction o f MTT to Formazan

MTT, (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), is a water
soluble tétrazolium salt yielding a pale yellow solution in media or saline
solutions lacking phenol red.

The mitochondrial dehydrogenases o f living cells

take up MTT and metabolize it to formazan, an insoluble purple product (Figure
4).
This conversion takes place in the inner mitochondrial membrane by the
enzymes o f the electron transfer chain (23). In the presence o f MTT, this chain is
disrupted and, the electrons are accepted by MTT, which undergoes reduction to
formazan (Figure 5). The formazan formed is solubilized using acid isopropanol
and measured spectrophotometrically using a plate reader at 570nm. The optical
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density directly corresponds to activity o f living cells relative to the control
(untreated cells).

Succinate^^^^

FADH 2
Succinate-CoQ Reductase
-> MTT

C y tc l
C oQ -C ytcl Reductase

-►MTT

C y tc

Cyt a/a3
Cyt c oxidase

OXYGEN
Figure 5

Points o f Interaction o f M TT with the Electron Transport Chain
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Experimental Procedure

About 1 x 1 0 * cells/200pl o f culture medium were seeded into wells o f a
96 well plate and incubated at 37°C for 24h. After 24 h, the medium was changed
and appropriate cultures were treated with various cytotoxic drugs and incubated
for 24-48h. At the end o f the incubation period, 20 pi o f MTT (5mg/ml) was
added and the plate was wrapped in aluminum foil and incubated at 37°C for 4h.
After the incubation period, 150 pi o f the media was removed and 150 pi o f
isopropyl alcohol:IN HCl (98:4) was added and the absorbance determined at
570nm using a microplate reader (Dynatech MR 5000). Results are presented as
a percentage o f the control.

Apoptosis Assay

Apoptosis was quantitated using an enzyme linked immunosorbent assay
(Boehringer Mannheim), which measures the cytoplasmic histone-bound DNA
fragments (mono and oligonucleosomes) generated during apoptotic DNA
fragmentation (Figure 6, page IT).

The presence o f these fragments in the

cytoplasm is a characteristic o f apoptosis and is a result o f endogenous
endonucleases being activated by the proteolytic cascade. Antibodies directed at
the DNA and histones in this “sandwich” assay, quantitatively determines
apoptotic death induced by the cytotoxic drug relative to the control (untreated
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cells). The two antibodies used in this assay are (1) Anti-histone antibody that
targets the histone and (2) Anti-DNA-peroxidase that targets the DNA.

The

amount of these fragments present in the cytoplasm i.e., the amount o f peroxidase
in the immunocomplex is determined photometrically by conjugation with ABTS
(2,2’-azino-di-[3-ethylbenzthiazolinesulfonate(6)]) as a substrate. The specificity
o f the antibodies to histone and DNA o f the nucleosomes was not studied here, as
we were interested in comparing the apoptosis induced in the Hsp 27 expressing
cell lines to the control transfected cell line.

Experimental Procedure

Cells were plated (1 x 10*cells/200 pi) into wells o f a 96-well plate. After
desired treatment, cytoplasmic extracts were made from both floating and
attached cells, according to manufacturer’s protocol. Briefly, drug treated cells
and untreated controls were lysed using a lysis buffer and centrifuged at 1000
r.p.m. for 10 minutes. Control and drug-treated cell extracts were equalized on
the basis o f equal cell number.

The wells were first coated with anti-histone

antibody, loaded with cytoplasmic extracts (centrifugate) and followed by
incubation with anti-DNA second antibody conjugated with peroxidase.

The

ELISA was developed with peroxidase substrate, and the absorbance at 405 nm
was measured using microplate autoreader (Dynatech MR5000).
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CHAPTER 3

RESULTS

Growth Inhibition o f Breast Cancer Cells in the Presence o f Sodium Butyrate

- Sodium butyrate, a short chain fatty acid, is produced in the colon by the
fermentation o f dietary fiber (24). Sodium butyrate and other short chain fatty
acids (SCFA) have been known to induce growth arrest and promote apoptosis in
many cell types including breast cancer cells (25-30). Sodium butyrate is non
toxic and hence can be used for therapeutic purposes. In this study, the effect o f
sodium butyrate on the growth o f breast cancer cells expressing Hsp 27 (DB 46
and DB 26) was investigated and compared to their control transfected
counterparts which do not express Hsp 27(DC 4 and DC 7). All cell lines were
treated continuously with various concentrations o f sodium butyrate for 24 h or 48
h. It has been reported that sodium butyrate causes growth arrest in the first 48 h,
continuous treatment beyond this point led to little additional reduction in cell
survival (26).

The growth inhibition was measured using the MTT assay as

described in Materials and Methods. As shown in Figure 7, (page 25), DC 4 cells
were more sensitive to sodium butyrate at 48 h (46% growth at the highest
concentration o f butyrate) than DB 46 cells (54% growth at the highest
18
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concentration o f butyrate). These results are from a single experiment performed
in triplicate. The experiment was repeated with DB 26 and DC 7 cells (Figure 8,
page 26). In this case however, the growth o f Hsp27 expressing cells (DB 26)
was not significantly higher than control transfected cells (DC 7) The validity o f
the results were tested by using a t-test (Appendix). The error bars correspond to
percentage deviation from the mean. At 24 h, however, the growth inhibition by
butyrate was lower, and any differences between the cell lines were not
statistically significant (Figure 9,page27 and Figure 10, page 28).

Apoptosis Induced by Sodium Butyrate

The ability o f Sodium Butyrate to induce apoptosis in our cell lines was
studied using the enzyme linked immunosorbent assay (ELISA) as described in
Materials and Methods. As shown in Figure 11 (page 29), Sodium Butyrate
treatment o f DB 46 and DC 4 for 20 hours stimulated apoptosis in a dose
dependent manner. The addition o f 10 mM Sodium Butyrate was able to increase
the rate o f apoptosis in the control transfected cell line (DC 4) by almost 6.5 fold
while in Hsp27 expressing cell line apoptosis was increased only 2 fold. These
results are from a single experiment performed in triplicate. DB 26 cells however
did not exhibit a dramatic resistance to butyrate.(Figure 12, page 30). These cells
exhibited higher apoptosis in the presence o f 3mM Sodium Butyrate (5.0 fold
increase in apoptosis) than the DB 46 cells (2.0 fold increase in apoptosis with
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respect to control). The differences in the Hsp 27 expressing cell lines (i.e., in
their response to butyrate) may be due to clonogenic variations (i.e., the exact
amount o f the protein present in different clones may be different).

Growth Inhibition by Staurosporine

Staurosporine, a microbial alkaloid induces its anti-cancer activity by the
inhibition o f protein kinase C (31). Protein kinases are a group o f enzymes that
catalyze the phosphorylation o f target proteins and regulate protein activity.
Protein kinase C, a calcium dependent protein kinase, phosphorylates proteins at
their serine and threonine residues. Diacylglycerol and tumor promoters such as
phorbol esters activate this enzyme.

Phorbol esters are structurally similar to

diacylglycerol but are not easily metabolized. Since protein kinase C has been
implicated in cellular proliferation (32), a persistent activation o f this enzyme by
phorbol esters leads to the formation o f tumors. Staurosporine is a potent protein
kinase C inhibitor (31) and induces growth arrest and apoptosis in a variety o f cell
lines (33-35).
To determine whether Hsp 27 could offset the anti-proliferative and
apoptotic potential o f Staurosporine, we treated Hsp 27 expressing and control
transfected breast cancer cells with micromolar amounts o f Staurosporine for a
period o f 24h.

Our results indicate that at the highest concentration (5pM),

Staurosporine had 93%-96% inhibition o f growth, as studied by the MTT assay.
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The Hsp 27 expressing cell lines did not have a higher tolerance for the drug
when compared to the control transfected cell lines.

Any differences seen

between the cell lines were not statistically significant (Figure 13, page 31 and
Figure 14, page 32). Each experiment was performed in triplicate and the error
bars represent the percent deviation from the mean.

Induction o f Apoptosis by Staurosporine

- Apoptosis was quantified using an ELISA that measures cytoplasmic
histone-bound DNA complexes generated during apoptotic DNA fragmentation.
As shown in Figure 15 (page 33), Staurosporine induced apoptosis in a dose
dependent manner in DB 46 cells whereas the DC 4 cells apoptosis increased
eleven fold for the lowest concentration (0.5pM ) and higher concentrations had
little effect in increasing apoptosis.

At the highest concentration used, the

protection offered by Hsp 27 in DB 46 cells no longer existed, in fact at this
concentration DB 46 cells had higher apoptosis than DC 4 cells. This result is
important therapeutically, as it tells us that higher concentrations o f the drug may
be used to treat patients having Hsp 27 positive tumors. Figure 16 (page 34)
shows the effect o f the drug on DB 26 and DC 7 cell lines. However, DC 7
(which is similar to DC 4) shows a dose response at all concentrations o f the drug
used.

At all concentrations o f the drug used DB 26 cells exhibited lower

apoptosis than the control transfected cells DC 7. The dramatic sensitivity seen in
DC 4 cells at lower concentrations o f the drug (11 fold increase in apoptosis at 0.5
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|iM ) was not seen in DC 7 ceils (only 4 fold increase in apoptosis at 0.5 pM).
Such differences may be attributed to clonogenic variations.

Growth Inhibition by Vitamin E Succinate

Vitamin E Succinate (RRR-a-tocopheryl succinate) is the succinate ester
o f Vitamin E. The succinate ester has been demonstrated to be a potent inhibitor
o f human breast cancer cell proliferation (36). The exact mechanism by which
Vitamin E Succinate (VES) inhibits proliferation is not known, but cell cycle
blockages, cellular differentiation, activation o f transforming growth factor-}) and
induction o f apoptosis is seen in VES treated cells. VES is mainly attractive for
its non-toxic effect on normal cell types. Since a lot o f recent work has focused
on the anti-tumor effect o f VES in breast cancer cells, we were interested in
knowing whether VES could exhibit the same effect or activity in Hsp 27
expressing breast cancer cells. In this study, we exposed Hsp 27 expressing and
control transfected cell lines to various concentrations o f VES continuously for
48-65 h.

After 48 h o f incubation, 90%-93% growth inhibition was seen at

40pg/ml o f VES (Figure 17, page 35).

When cells were exposed to 5pg/ml -

30 pg/ml o f VES for 65 h (Figure 18, page 36 and Figure 19, page 37), they
showed a similar response. The highest growth inhibition seen for all four cell
lines was at 15 pg/ml. At all concentrations, however, Hsp 27 expressing cell
lines had higher tolerance for the drug than the control transfected cell lines. The
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growth inhibition at various concentrations was normalized to a control, which
had succinic acid at the same concentration as the highest concentration o f VES
used. At 65h, the growth inhibition seen in the presence o f VES was higher than
the growth inhibition seen for the same concentrations at 48 h.

Growth Inhibition by Cycloheximide

Cycloheximide is an antibiotic that inhibits protein biosynthesis.

The

exact mechanism as to how the inhibition o f protein synthesis turns on the
apoptotic cascade is not known. An explanation that has been put forward is that
Cycloheximide blocks the synthesis o f inhibitor proteins that regulate the
endogenous endonucleases (37). When the levels o f the inhibitor proteins fall, the
endonucleases are activated and apoptosis follows. It has also been reported that
some cells are programmed to die in the absence o f inhibitor proteins (38). In our
study, the effect o f Hsp 27 on growth inhibition induced by Cycloheximide was
studied using the MTT assay.

Human breast cancer cells that constitutively

express Hsp 27 and their control transfected counterparts were treated with
25pM -200pM o f Cycloheximide for a period o f two hours and then allowed to
grow for 24h-65h.

Figure 20 (page 38) and Figure 21 (page 39) shows the

percentage growth o f cells 24h after the Cycloheximide treatment. The growth in
both cases was normalized to a control that was treated with 0.1%v/v with
ethanol. The cells that expressed Hsp 27 showed a higher percentage o f growth
than the control transfected cell lines at all concentrations o f the drug studied.
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The error bars were the percent deviation from the mean o f the experiment set in
triplicate. Figure 22 (page 40) and Figure 23 (page 41) show the effect o f twohour pulse o f Cycloheximide studied after 65 h. The DB 26 cells (Figure 23) did
not show a significantly higher growth when compared to the control transfected
DC 7 cells. In all other cases, (Figures 20-22) Hsp 27 expressing breast cancer
cells had a higher resistance to the drug than their control transfected
counterparts.
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Figure 7

Percentage growth o f DB 46 and DC 4 cells 48h after treatment
with butyrate. The error bars represent percent deviation from
mean (n=3). (•: p<0.05). OD for untreated controls: (DB 46: 0.461
and DC 4: 0.451)
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Figure 8

Percentage growth o f DB 26 and DC 7 cells 48h after treatment
with butyrate. O.D. for untreated controls: (DB 26: 0.474 and
DC 7: 0.347). (*:p=0.05)
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Figure 9

Percentage growth o f DB 46 and DC 4 cells 24h after treatment
with butyrate. The error bars represent percent deviation from
mean (n=3). (• : p=0.05). O.D. for untreated controls: (DB 46:
0.334 and DC 4: 0..275)
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Figure 10

Percentage growth o f DB 26 and DC 7 cells 24h after treatment
with butyrate. The error bars represent percent deviation from
mean (n=3). (• : p<0.05). O.D. for untreated controls: (DB 26:
0.305 and DC 4: 0..254)
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Figure 11

Fold increase in apoptosis o f DB 46 and DC 4 cells 20h after
treatment with butyrate. The error bars represent standard
deviation from mean (n=3). (• : p<=0.05). O.D. for serum
control:0.364
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Figure 12

Fold increase in apoptosis o f DB 26 and DC 7 cells 24h after
treatment with butyrate. The error bars represent standard
deviation from mean (n=3). (• : p = 0.05). O.D. for serum
control;0.313
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Figure 13

Percentage growth o f DB 46 and DC 4 cells 24h after treatment
with Staurosporine. The error bars represent percent deviation
from mean (n=3). (♦ too few data values to determine statistical
significance). O.D. for untreated controls:(DB 46: 0.272 and DC 4:
0.288)
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Figure 14

Percentage growth o f DB 26 and DC 7 cells 24h after treatment
with Staurosporine. The error bars represent percent deviation
from mean (n=3). (, : p <=0.05). O.D. for untreated controls:(DB
26; 0.278 and DC 7; 0.214)
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Figure 15

Fold increase in apoptosis o f DB 46 and DC 4 cells 24h after
treatment with Staurosporine. The error bars represent standard
deviation from mean (n=3). (• : p <= 0.05). O.D. for serum
control: 0.240
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Figure 16

Fold increase in apoptosis o f DB 26 and DC 7 cells 24h after
treatment with Staurosporine. The error bars represent standard
deviation from mean (n=3). O.D. for serum control: 0.240
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Figure 17

Percentage growth o f DB 46 and DC 4 cells 48 h after treatment
with VES. The error bars represent percent deviation from mean
(n=3). (.: p=0.05). O.D. for untreated controls:(DB 46: 0.407 and
DC 4: 0.325)
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Figure 18

Percentage growth o f DB 46 and DC 4 cells 65h after treatment
with VES. The error bars represent percent deviation from mean
(n=3). (• : p <=0.05). O.D. for untreated controls:(DB 46: 0.609
and DC 4: 0.551)
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Figure 19

Percentage growth o f DB 26 and DC 7 cells 65h after treatment
with VES. The error bars represent percent deviation from mean
(n=3). (* : p <=0.05). O.D. for untreated controls:(DB 26: 0.638
and DC 4: 0.498)
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Figure 20

Percentage growth o f DB 46 and DC 4 cells 24h after a 2 hour
treatment with Cycloheximide. The error bars represent percent
deviation from mean (n=3). (♦ ; p<=0.05). O.D. for untreated
controls:(DB 46: 0.184 and DC 4: 0.202)
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Figure 21

Percentage growth o f DB 26 and DC 7 cells 24h after a 2 hour
treatment with Cycloheximide. The error bars represent percent
deviation from mean (n=3). (• : p < = 0.05). O.D. for untreated
controls:(DB 26: 0.225 and DC 7: 0.461)
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Figure 22

Percentage growth o f DB 46 and DC 4 cells 65h after a 2 hour
treatment with Cycloheximide. The error bars represent percent
deviation from mean (n=3). (• : p <= 0.05). O.D. for untreated
controls:(DB 46: 0.426 and DC 4: 0.511)
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Figure 23

Percentage growth o f DB 26 and DC 7 cells 65h after a 2 hour
treatment with Cycloheximide. The error bars represent percent
deviation from mean (n=3). (• : p < 0.01). O.D. for untreated
controls:(DB 26; 0.631 and DC 7: 0.473)
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CHAPTER4

DISCUSSION

Hsp 27 protects the cells from stresses such as heat shock and
chemotherapeutic agents (15-17). This study focuses on yet another aspect o f the
protection offered by this protein - its ability to inhibit programmed cell death or
apoptosis. It has been reported that the presence o f Hsp 27 in breast cancer cells
has correlated to a shorter disease free survival and as a marker for more
aggressive tumors (19). In order to understand the extent o f protection offered by
Hsp 27 against various cytotoxic drugs, we used human breast cancer cells that
constitutively express Hsp 27. These cells were constructed from the estrogen
receptor negative human breast cancer cell line MDA-MB-231 which expresses
very low endogenous levels o f Hsp 27.

MDA-MB-231 cells were transfected

with the constitutive expression vector pP27 containing the human Hsp 27 cDNA
sequence or with a control vector pHpApr-l-neo lacking the cDNA sequence
(21). The constitutive expression o f Hsp 27 has been reported to protect breast
cancer cells from heat induced cytotoxicity and also decrease the time required to
resume protein synthesis (17).

Others have reported a similar finding using

different cell lines.
42
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One o f the methods that Hsp 27 may confer protection is by inhibiting cell
death - either necrosis or apoptosis. Since many o f the chemotherapeutic drugs
work by inducing apoptosis, we treated our cells with various cytotoxic drugs
which have been reported to induce apoptosis in other cell lines, to see whether
Hsp 27 could offset the drug’s effect. We measured the growth inhibition caused
by the drug, at first, as an inexpensive indicator o f apoptosis and later measured
apoptosis induced in some o f the systems using an ELISA. The significance o f
the data obtained was measured using a t-test (Appendix).
In some cases studied, breast cancer cells expressing Hsp 27 had a higher
growth in the presence o f the cytotoxic drugs. Each o f the drugs chosen induced
apoptosis in other cell lines by different mechanisms (Figure 24, page 52). In
order to have a fair understanding o f the point(s) at which Hsp 27 may be acting
in the apoptotic cascade to inhibit the onset o f apoptosis, I wish to treat each drug
separately.

Hsp 27 Confers Resistance against Butyrate Induced Apoptosis

Sodium Butyrate is a dietary micronutrient produced by the microbial
fermentation o f fiber.

Sodium Butyrate and other short chain fatty acids have

been reported to induce growth arrest, differentiation and apoptosis in colonic
cancer and breast cancer cell lines (25-30).

The exact mechanism o f butyrate

induced apoptosis and growth arrest is not yet known. It has been reported that
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butyrate’s action is tightly linked to mitochondrial function (27,28). Inhibition o f
mitochondrial function, by using inhibitors that blocked the mitochondrial
electron transport, oxidative phosphorylation and cytochrome c, within 8h o f
butyrate treatment decreased butyrate induced apoptosis in colonic cancer cells
(28). The growth arrest occurs simultaneously at the Go-Gi and Ga-M o f the cell
cycle in colonic cancer cells. Breast cancer cells, irrespective o f their steroid
receptor profiles, were blocked at the Ga-M phase o f the cell cycle (29). In the
same study by Coradini et al. however, only estrogen receptor positive MCF 7
and T47D underwent apoptosis in the presence o f butyrate as detected by gel
electrophoresis.

We observe that the estrogen receptor negative breast cancer

cells also undergo apoptosis within 24h o f treatment with Sodium Butyrate. The
difference in the results may be because o f the method used in detecting
apoptosis.

We used the ELISA system that measures the cytoplasmic histone

bound DNA fragments generated during apoptosis, a method that may detect
DNA fragmentation even when the classic ladder pattern is not seen on the
agarose gel.

It has also been reported that butyrate functions as an apoptotic

inducer by blocking histone deacetylase in Jurkat lymphoid, colorectal and colon
cancer cells (26, 27).

When the function o f histone deacetylase is inhibited,

histone (H4) is hyperacetylated leading to a more open chromatin structure, which
opens up the linker regions to endogeneous endonucleases (27). Apoptosis
induced in these cell lines is strictly dependent on protein synthesis and activation
o f caspase 3 and is dependent on a cytochrome c dependent pathway Q.1) (see
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page 52).

The effect o f butyrate induced apoptosis is regulated by Bcl-2, a

protein that inhibits apoptosis by inhibiting the transport o f cytochrome c from
mitochondria to the cytosol (25).
In our study, we observe that human breast cancer cells that express Hsp
27 underwent less apoptosis in the presence o f butyrate. Since butyrate functions
at the level o f mitochondria, Hsp 27 may be functioning at the same level or
downstream o f mitochondria to offset the effect o f Sodium Butyrate.
Since induction o f apoptosis by butyrate is dependent on cytochrome c dependent
pathway which is blocked by bcl-2, it might be interesting to look at whether Hsp
27 has any effect on the release o f cytochrome c from the mitochondria.

Hsp 27 Confers Resistance against Staurosporine

Staurosporine, a microbial alkaloid is an inhibitor o f a wide range o f
protein kinases including protein kinase C, cyclin dependent kinases(cdks), cyclic
AMP dependent kinases and p60 v-src protein tyrosine kinase. Protein kinases
regulate an array o f functions, one o f which is progression through cell cycle by a
family o f cdks. The exact function o f protein kinase C (PKC) has been addressed
previously {see page 20). It has been reported that Staurosporine causes growth
arrest at the Gi phase o f the cell cycle in breast cancer cells and HeLa cells (33).
The growth arrest has been reported to result from an induction o f p 2 1 protein and
also due to the loss in catalytic activity o f the cdks (33,39).

p21 is a potent
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inhibitor o f cdks and associates with various cyclin-cdk complexes to inhibit the
kinase activity o f these complexes. Staurosporine and its analogues have been
reported to alter the cellular localization o f certain PKC isoforms and inhibit their
activity (32,35). Staurosporine and its hydroxy derivative, however, have been
known to activate one o f the PKC isoforms, the PKC a . This activation has been
reported to occur downstream from caspases in myeloid leukemia cells as
inhibitors o f caspases blocked the activation o f PKC a (35). In other studies, with
cardiomyocytes, it was found that Staurosporine activates caspase 3.

This

activation o f caspase 3 may be upstream o f the activation o f PKC a . It has also
been reported that caspase 3 cleaves PKC Ô and that this is responsible for the
morphological features associated with apoptosis (40).
In our study, estrogen receptor negative breast cancer cells that
constitutively express Hsp 27 lower apoptosis than the control transfected cell
lines (Figure 15). At the highest concentration o f Staurosporine used however,
the protection was not observed.

This may be because 5pM Staurosporine is

highly cytotoxic and offsets the protection offered by Hsp 27.

Constitutive

expression o f Hsp 27 also confers resistance to apoptotic cell death induced by
Staurosporine in murine L929 cells. Ongoing research in our labs indicate that
Hsp 27 expressing breast cancer cells exhibit lower caspase 3 activity in the first
8h o f treatment with cytotoxic drugs than the control transfected cell lines (Joe
Stafford, personal communications). This suggests that Hsp 27 may be conferring
resistance to Staurosporine by blocking the activation o f caspase 3.

Higher
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concentrations or longer incubation times with the dmg may abrogate this effect
as caspase 3 showed peak activity after 24h o f incubation with cytotoxic drugs.

Hsp 27 Confers Resistance against Vitamin E Succinate

Vitamin E Succinate has been studied widely for its ability to induce
growth arrest and apoptosis in a variety o f cell lines. The exact mechanism by
which VES induces apoptosis is not fully known. Recent reports on the effect o f
VES in breast cancer cells have shown that VES enhances the expression of
transforming growth factor-)) (TGF-P) and its isoforms (36,41,42). TGF-P and its
isoforms form a family o f growth factors that inhibit the proliferation of
epithelial, lymphoid and endothelial cells.

Malignant transformation has been

thought to occur when cells escape the growth-inhibitory effects o f TGF-P by
either inactivation o f the genes encoding for the factor or its receptor.
Compounds that stimulate the TGF-P have included retinoids, deltanoids
(Vitamin D and its analogues), tamoxifen (antiestrogen) and gestodene (synthetic
progestin)(36).

Recently, VES has been added to the list o f these terpene

compounds that can stimulate TGF-P (42). It has also been reported that VES
elevates the levels o f c-jun (mRNA and protein) and enhances activator protein -1
(AP-1) binding in a variety o f cell lines (42). c-jun is an important member in the
AP-I transcription factor family that has been implicated in cell proliferation,
differentiation, transformation and recently in apoptosis. c-jun can be transiently
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activated by growth factors to increase proliferation in cells.
c-jun is activated by the growth factors through the JNK pathway (Jun N
terminal kinase) also knovm as the SAPK (stress activated protein kinase)
pathway to cause an increase in proliferation.

When JNK is triggered by

apoptotic inducers it turns on c-jun by phosphorylation at its serine residue and
causes cell death via apoptosis.

How the same signaling mechanism causes

opposing fates in cells is unknown. One theory is that sustained JNK activation
(as seen in the case o f apoptotic inducers) induces apoptosis while transient
activation (as seen in the case o f growth factors) induces proliferation(42).
We observed growth inhibition in breast cancer cells in the presence o f
VES. The growth inhibition seen in the case o f Hsp 27 expressing cells was
higher than that seen in the non Hsp 27 expressing cells. Apoptosis was measured
at 48h and 65h by an ELISA (data not shown)

A significant induction in

apoptosis was not seen at times and concentrations o f the drug used.

Hsp 27 Confers Resistance against Cycloheximide

Cycloheximide also known as actidone is a glutarimide antibiotic that
inhibits protein synthesis in systems that use 80S ribosomes (43). Cycloheximide
has been know to induce apoptosis in human breast cancer cells (37). Apoptosis
is caused in these cells by the inhibition o f protein synthesis. Apoptosis may be
turned on when the inhibitor proteins that regulate endonucleases are not
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produced in sufficient amounts due to blocked protein synthesis. Cycloheximide
has also been reported to interfere with glucose transport which in turn influences
cell death. The exact nature o f this effect is not yet elucidated. Contrary to its
pro-apoptotic function, Cycloheximide has been recently reported to inhibit
apoptosis in systems that require new protein synthesis to activate caspases (44).
This discrepancy in its function is still not understood.
In human breast cancer cells, Cycloheximide induces a growth inhibition
at all concentrations used. However, cells expressing Hsp 27 were able to better
survive at all concentration o f the drug than the control transfected counterparts.
Apoptosis was measured using ELISA at 48 h and 65h, but no induction o f
apoptosis was seen at the times and concentrations o f the drug used (data not
shown).

Conclusions

We report that Hsp 27 when present in human breast cancer cells protects
these cells from a variety o f cytotoxic inducers acting at different points o f the
apoptotic pathway (see Table \,p a g e 5J). Constitutive expression o f Hsp 27 has
been reported to protect murine cells from Fas/APO-1 induced apoptosis, U937
and Wehi-s cells from camptothecin, etoposide and actinomycin D and human
breast cancer cells from heat shock (4,5,21). Since Hsp 27 can protect different
cells from a variety o f stresses that induces apoptosis, it might be acting
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downstream from these inducers or may be acting at different points in the
apoptotic pathway. It has also been reported that Hsp 27 expression decreased
intracellular - reactive oxygen species and increase the cellular content o f the
antioxidant glutathione(4). The presence o f the antioxidant glutathione appears to
be essential for the protective activity against TNF a and oxidative stress induced
cell death. The stimulation o f anti-oxidants may be the way in which Hsp 27
protects cells from apoptosis. It has also been reported that Hsp 27 is an actin cap
binding protein(45). Actin is one o f the substrates cleaved by caspases when
apoptosis is turned on. Protection o f actin from caspases may be responsible for
the anti-apoptotic function o f Hsp 27. A clear knowledge o f the role o f Hsp 27 is
not known, the knowledge o f its function and the point(s) at which it acts would
be crucial in developing adjuvant therapies that target this protein in cancer cells.
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Table 1

Summary o f Results
Cell lines

Drug

Time (h)

Results"
Growth

Apoptosis

DB 46 & DC 4

NAB

48 h

DB 26 & DC 7

NAB

48 h

:

DB 46 & DC 4

NAB

24 h

❖

DB 26 & DC 7

NAB

24 h

»:♦

DB 46 & DC 4

STR

24 h

♦

DB 26 & DC 7

STR

24 h

♦

El

DB 46 & DC 4

VES

48 h

❖

O

DB 46 & DC 4

VES

65 h

DB 26 & DC 7

VES

65 h

DB 46 & DC 4

CHX

24 h

DB 26 & DC 7

CHX

24 h

DB 46 & DC 4

CHX

65 h

DB 26 & DC 7

CHX

65 h

X

H
X

X

:
X

O
o

X

X

X

❖

o
o

{K: Significant difference seen in growth between the two cell lines at all
concentrations, ❖: differences between the two cell lines significant only at
certain concentrations, ♦ ; too few data values to evaluate the statistical
significance, E l: no significant differences between cells, O : apoptosis not
induced at the times and concentration studied, NAB: butyrate, STR:
Staurosporine, VES: Vitamin E Succinate, CHX: Cycloheximide}
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APPENDIX

CALCULATION OF STATISTICAL SIGNIFICANCE

In order to determine the statistical significance between the growth rates
and apoptosis o f the DB cell lines (which constitutively express Hsp 27 ) and DC
cell lines (which lack the constitutive expression vector), the student's t-test is
used.

The student's t-test is generally used to test the hypotheses for mean

difference between a set o f paired experimental results. In this study all the cell
lines were derived from estrogen receptor negative MDA-MB-231 human breast
cancer cells. The only difference between the DB cells lines and the DC cell lines
is the presence o f Hsp 27 cDNA sequence. Hence we considered the DB cell
lines and DC cell lines as two sets o f samples and any significant difference
between their growth rates and apoptosis is attributed to the presence o f Hsp 27 in
DB cell lines.

This statistical hypotheses is tested assuming normality in the data values
and the two mean values are independent from each other with unknown and
equal variances. The equation used is given below;
53
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<»
+ —

where

«, = number o f observations comprising the first average x,
«: = number o f observations comprising the second average x.
Sp= pooled standard deviation o f the standard deviations s, and
s, for the first and second sets o f data

(«I - l)j,- + («2 -1)^2

The t value obtained from this calculation is compared with the tp given in
Table 4, Appendix III {Introduction to Probability and Statistics, by Mendenhall
and Beaver, 1990). The p value determines the significance level. If the t value
exceeded the tp value, then the hypotheses is rejected because the mean values of
the two samples are significantly different at p value specified.
In our study, the growth rates o f the DB and DC cell lines in the presence o f the
drug is normalized to an untreated control before performing the t-test.

This

normalization prevents the differences (growth rates, survival etc., ) between the
cell lines from affecting the results seen.
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Sample Calculation

A sample calculation is presented to demonstrate the methodology
adopted for calculating the statistical significance o f the experimental data. The
primary objective for using the t-test was to determine if Hsp 27 expressing cell
lines were significantly different from control transfected cell lines in their
response to various drugs. The results from the following example is presented in
Figure 7.
DB 46 is the Hsp 27 expressing breast cancer cell line and DC 4 is the Control
transfected cell line. The following data is the O.D. values as measured by the
plate reader. The average, standard deviation (SD), % deviation (% SD) and %
growth (%G) were calculated manually.
DB 46

DC 4
control

DB 46 ImM

DC 4 ImM

0.416

0.414

0.401

0.363

0.483

0.452

0.424

0.332

0.489

0.476

0.437

0.347

0.455

0.463

0.432

0.350

0.461

0.451

0.424

0.348

Average

0.033

0.027

0.016

0.013

SD

100.00

100.00

91.86

77.16

%G

7.230

5.917

3.761

3.657

% SD

control

Raw data as
read by the
plate reader
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Calculation o f % Growth and % Deviation

The growth o f untreated controls was set to a hundred percent and all the drug
treated cells were normalized to this control,
i.e..
For DB 46 cells, the untreated control had an average O.D. o f 0.461.
Growth was measured by the MTT assay where the sample O.D. corresponds to
amount o f living cells. Hence O.D. o f 0.461 was set to 100% growth and drug
treated DB 46 cells were compared to this control.
For DC 4 cells, the untreated control had an O.D. o f 0.451 which was set
to 100%. The drug treated DC 4 cells were normalized using this value.
Therefore,
% growth o f DB 46 cells in the presence o f ImM Sodium Butyrate is:
((0.424/0.461)* 100)=91.86
Similarly, % growth o f DC 4 cells in the presence o f ImM Sodium Butyrate is:
((0.348/0.451)*100)=77.16
The percent deviation was calculated using the following equation
% SD = (Standard deviation/Average)* 100
All other data points in Figure 7 and all other figures have been treated in the
same fashion.
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Calculation o f t

t was calculated using equations (1) and (2). Taking the same example, as before.
Raw Data

Normalized data

DB46 cont.

DC4 cont.

DB 46 ImM

DC 4 ImM

DB 46 ImM

DC 4 ImM

0.416

0.414

0.401

0.363

0.870

0.805

0.483

0.452

0.424

0.332

0.920

0.736

0.489

0.476

0.437

0.347

0.948

0.769

0.455

0.463

0.432

0.350

0.937

0.776

0.919

0.772

0.035

0.028

Average
0.461

0.451
Standarc Deviation

0.033

0.027

Number o f degrees o f freedom (nl and n2)
4.00

4.00
’ooled standard deviation >p)
0.030
t
6.592

As described previously, the drug treated cells o f each cell line was
normalized to its respective untreated controls. The t test was performed on the
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normalized data values and not the raw data. The calculated value o f t was
compared to accepted values o f t at 90%-99% confidence levels. If the calculated
value o f t was greater than accepted values o f t at the confidence levels used, the
averages (of the cell lines compared) were significantly different from each other.
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